T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION

T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION

Abstract Background Previous studies showed a direct correlation between partial compliance with an oral antipsychotic medication and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior. Long Acting Injections (LAIs) may enhance compliance and reduce rela...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Schizophrenia bulletin 2019-04, Vol.45 (Supplement_2), p.S246-S247
Hauptverfasser: Pappa, Sofia, Mason, Katy
Format: Artikel
Sprache:eng
Schlagworte:
Poster Session I
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S247
container_issue Supplement_2
container_start_page S246
container_title Schizophrenia bulletin
container_volume 45
creator Pappa, Sofia
Mason, Katy
description Abstract Background Previous studies showed a direct correlation between partial compliance with an oral antipsychotic medication and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior. Long Acting Injections (LAIs) may enhance compliance and reduce relapse. The aim of this study was to evaluate the relationship between compliance with LAI 1-monthly Paliperidone Palmitate (PP1M) and risk of discontinuation and hospitalization. Methods This was a naturalistic, 6-year mirror-image study examining retention, compliance & hospitalization rates 3 years pre and 3 years post PP1M initiation. Compliance was divided in four groups: full (no missed dose/year), good (>6 injections/year), poor (
doi_str_mv 10.1093/schbul/sbz019.392
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6455417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/schbul/sbz019.392</oup_id><sourcerecordid>10.1093/schbul/sbz019.392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1772-23836969915c24a3c0362652e5d767e6cc6a1aa6363e790642819ab8aa7b60ff3</originalsourceid><addsrcrecordid>eNqNkNFKwzAUhoMoOKcP4F0ewG45SZs0N0Kp3Rat7XRVwZuQZq2bbOtoN0Gf3o6K4J1X_4H_fP_Fh9AlkAEQyYaNXeT71bDJvwjIAZP0CPVAuJ4DgsAx6hHP547g4J6is6Z5JwRcyWkPPWQAdIDj6DmKcTrCYXo_jVWQhBF-UdkEx2kyxkGYqTZUchu1V5rMcJDc4Ec1uzsgk3Q2VVkQq9fgUJ6jk9KsmuLiJ_voaRRl4cSJ07EKg9ixIAR1KPMZl1xK8Cx1DbOEcco9WnhzwUXBreUGjOGMs0JIwl3qgzS5b4zIOSlL1kfX3e52n6-LuS02u9qs9LZerk39qSuz1H-bzXKh36oPzV3Pc0G0A9AN2Lpqmroof1kg-iBVd1J1J1W3UlvmqmOq_fYf799WsXT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Pappa, Sofia ; Mason, Katy</creator><creatorcontrib>Pappa, Sofia ; Mason, Katy</creatorcontrib><description>Abstract Background Previous studies showed a direct correlation between partial compliance with an oral antipsychotic medication and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior. Long Acting Injections (LAIs) may enhance compliance and reduce relapse. The aim of this study was to evaluate the relationship between compliance with LAI 1-monthly Paliperidone Palmitate (PP1M) and risk of discontinuation and hospitalization. Methods This was a naturalistic, 6-year mirror-image study examining retention, compliance &amp; hospitalization rates 3 years pre and 3 years post PP1M initiation. Compliance was divided in four groups: full (no missed dose/year), good (&gt;6 injections/year), poor (&lt;6 injections/year) and non-compliance (no injection/year). Results 173 consecutive patients were included. 120 (70%) patients had a primary diagnosis of schizophrenia and 53(30%) had other diagnosis. In total, 77% of patients continued PP1M for 1 year, 66% for 2 years and 55% for 3 years. Out of 173 patients, 122 patients (71%) were fully compliant, 21 (12%) were generally compliant, 13 patients (7%) were poorly compliant and 17(10%) were completely non-compliant. The discontinuation rate at 3 years was 37% for patients with full compliance, 33% with good and 70% with poor compliance. The reduction in number and length of admissions was statistically significant for the group of patients that was fully compliant but not for the group with good or poor compliance. In the patients who were fully compliant the mean number of hospital admissions decreased from 1.9 to 0.6 and the mean number of bed days from 70 to 40 bed days per patient 3 years before and 3 years after PP1M initiation (P&lt;0.001). Discussion There was a linear association between level of compliance and risk of re-hospitalization. More than two thirds of this naturalistic cohort were fully compliant. This group demonstrated the best outcomes in terms of reduced hospitalizations with more than half of the patients having no admission during 3 years follow up. Patients with poor compliance had the worst outcomes: they were twice as likely to have completely discontinued PP1M at 3 years as well as showing the highest hospitalization rates both before and after PPM1 initiation.</description><identifier>ISSN: 0586-7614</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/schbul/sbz019.392</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Poster Session I</subject><ispartof>Schizophrenia bulletin, 2019-04, Vol.45 (Supplement_2), p.S246-S247</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455417/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455417/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1584,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Pappa, Sofia</creatorcontrib><creatorcontrib>Mason, Katy</creatorcontrib><title>T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION</title><title>Schizophrenia bulletin</title><description>Abstract Background Previous studies showed a direct correlation between partial compliance with an oral antipsychotic medication and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior. Long Acting Injections (LAIs) may enhance compliance and reduce relapse. The aim of this study was to evaluate the relationship between compliance with LAI 1-monthly Paliperidone Palmitate (PP1M) and risk of discontinuation and hospitalization. Methods This was a naturalistic, 6-year mirror-image study examining retention, compliance &amp; hospitalization rates 3 years pre and 3 years post PP1M initiation. Compliance was divided in four groups: full (no missed dose/year), good (&gt;6 injections/year), poor (&lt;6 injections/year) and non-compliance (no injection/year). Results 173 consecutive patients were included. 120 (70%) patients had a primary diagnosis of schizophrenia and 53(30%) had other diagnosis. In total, 77% of patients continued PP1M for 1 year, 66% for 2 years and 55% for 3 years. Out of 173 patients, 122 patients (71%) were fully compliant, 21 (12%) were generally compliant, 13 patients (7%) were poorly compliant and 17(10%) were completely non-compliant. The discontinuation rate at 3 years was 37% for patients with full compliance, 33% with good and 70% with poor compliance. The reduction in number and length of admissions was statistically significant for the group of patients that was fully compliant but not for the group with good or poor compliance. In the patients who were fully compliant the mean number of hospital admissions decreased from 1.9 to 0.6 and the mean number of bed days from 70 to 40 bed days per patient 3 years before and 3 years after PP1M initiation (P&lt;0.001). Discussion There was a linear association between level of compliance and risk of re-hospitalization. More than two thirds of this naturalistic cohort were fully compliant. This group demonstrated the best outcomes in terms of reduced hospitalizations with more than half of the patients having no admission during 3 years follow up. Patients with poor compliance had the worst outcomes: they were twice as likely to have completely discontinued PP1M at 3 years as well as showing the highest hospitalization rates both before and after PPM1 initiation.</description><subject>Poster Session I</subject><issn>0586-7614</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkNFKwzAUhoMoOKcP4F0ewG45SZs0N0Kp3Rat7XRVwZuQZq2bbOtoN0Gf3o6K4J1X_4H_fP_Fh9AlkAEQyYaNXeT71bDJvwjIAZP0CPVAuJ4DgsAx6hHP547g4J6is6Z5JwRcyWkPPWQAdIDj6DmKcTrCYXo_jVWQhBF-UdkEx2kyxkGYqTZUchu1V5rMcJDc4Ec1uzsgk3Q2VVkQq9fgUJ6jk9KsmuLiJ_voaRRl4cSJ07EKg9ixIAR1KPMZl1xK8Cx1DbOEcco9WnhzwUXBreUGjOGMs0JIwl3qgzS5b4zIOSlL1kfX3e52n6-LuS02u9qs9LZerk39qSuz1H-bzXKh36oPzV3Pc0G0A9AN2Lpqmroof1kg-iBVd1J1J1W3UlvmqmOq_fYf799WsXT8</recordid><startdate>20190409</startdate><enddate>20190409</enddate><creator>Pappa, Sofia</creator><creator>Mason, Katy</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190409</creationdate><title>T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION</title><author>Pappa, Sofia ; Mason, Katy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1772-23836969915c24a3c0362652e5d767e6cc6a1aa6363e790642819ab8aa7b60ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Poster Session I</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pappa, Sofia</creatorcontrib><creatorcontrib>Mason, Katy</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pappa, Sofia</au><au>Mason, Katy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION</atitle><jtitle>Schizophrenia bulletin</jtitle><date>2019-04-09</date><risdate>2019</risdate><volume>45</volume><issue>Supplement_2</issue><spage>S246</spage><epage>S247</epage><pages>S246-S247</pages><issn>0586-7614</issn><eissn>1745-1701</eissn><abstract>Abstract Background Previous studies showed a direct correlation between partial compliance with an oral antipsychotic medication and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior. Long Acting Injections (LAIs) may enhance compliance and reduce relapse. The aim of this study was to evaluate the relationship between compliance with LAI 1-monthly Paliperidone Palmitate (PP1M) and risk of discontinuation and hospitalization. Methods This was a naturalistic, 6-year mirror-image study examining retention, compliance &amp; hospitalization rates 3 years pre and 3 years post PP1M initiation. Compliance was divided in four groups: full (no missed dose/year), good (&gt;6 injections/year), poor (&lt;6 injections/year) and non-compliance (no injection/year). Results 173 consecutive patients were included. 120 (70%) patients had a primary diagnosis of schizophrenia and 53(30%) had other diagnosis. In total, 77% of patients continued PP1M for 1 year, 66% for 2 years and 55% for 3 years. Out of 173 patients, 122 patients (71%) were fully compliant, 21 (12%) were generally compliant, 13 patients (7%) were poorly compliant and 17(10%) were completely non-compliant. The discontinuation rate at 3 years was 37% for patients with full compliance, 33% with good and 70% with poor compliance. The reduction in number and length of admissions was statistically significant for the group of patients that was fully compliant but not for the group with good or poor compliance. In the patients who were fully compliant the mean number of hospital admissions decreased from 1.9 to 0.6 and the mean number of bed days from 70 to 40 bed days per patient 3 years before and 3 years after PP1M initiation (P&lt;0.001). Discussion There was a linear association between level of compliance and risk of re-hospitalization. More than two thirds of this naturalistic cohort were fully compliant. This group demonstrated the best outcomes in terms of reduced hospitalizations with more than half of the patients having no admission during 3 years follow up. Patients with poor compliance had the worst outcomes: they were twice as likely to have completely discontinued PP1M at 3 years as well as showing the highest hospitalization rates both before and after PPM1 initiation.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/schbul/sbz019.392</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0586-7614
ispartof Schizophrenia bulletin, 2019-04, Vol.45 (Supplement_2), p.S246-S247
issn 0586-7614
1745-1701
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6455417
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Poster Session I
title T112. LEVEL OF COMPLIANCE WITH LONG ACTING INJECTIONS AND RISK OF HOSPITALIZATION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A13%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T112.%20LEVEL%20OF%20COMPLIANCE%20WITH%20LONG%20ACTING%20INJECTIONS%20AND%20RISK%20OF%20HOSPITALIZATION&rft.jtitle=Schizophrenia%20bulletin&rft.au=Pappa,%20Sofia&rft.date=2019-04-09&rft.volume=45&rft.issue=Supplement_2&rft.spage=S246&rft.epage=S247&rft.pages=S246-S247&rft.issn=0586-7614&rft.eissn=1745-1701&rft_id=info:doi/10.1093/schbul/sbz019.392&rft_dat=%3Coup_pubme%3E10.1093/schbul/sbz019.392%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/schbul/sbz019.392&rfr_iscdi=true